## Fagron Advanced Derma

## Compatibility table

LEGEND  Compatible combination for	SKIN TYPES Oily ski	n	Balanced skin	Dehv	drated skin	Very dehydra	ted skin	Affected skin	Spec	ific skin area
<ul><li>15 days</li><li>120 days</li><li>30 days</li><li>150 days</li></ul>	Olly 3ki	"	Dalaticea skiii	Delly	diated skiii	very derivara		Allected 3km	Орес	ine skin area
0 60 days 0 180 days 0 90 days		OCCLUVAN™	EMOLIVAN™	VERSATILE™ RICH	VERSATILE™	NOURIVAN™ ANTIOX	FITALITE™	CLEODERM™	SERAQUA™	ESPUMIL™
★ Especially recommended	(S)	Press PROCEDURE CONTINUES SAIL 1985	EMOCKVAN*  Ny WY MA MYD CODD CHAM MOC (WE	VERSATILE* BICH  Typ. (NECHED CAY CREAM BASE 1985)	WESTER  Typ. WINDOWS CONTROL DESCRIPTION	NOURPLAN* ANTIOX  By, MODRISON OVER CRAM SRI 595	FITALITY  THE NATIONAL COLCUMN SAME SAME	CIFODERM"		Special Specia
combination % Compatible	TION	Figure MOCHANIC CONCURS (MAIL 1955    The Concurs of the Concurs o	Type NO. RAM. MOV. COSD CESAN BUX. 1995  The Cost of t	Figure INVECTOON CREAM BASE - NASE  THE STATE OF THE STAT	Figure VANCO-FIGURE CONTROL CO	The second of th	Page MILLOR CR. CRAM ADD 2-376 F	TREADING (CAMA SEL S)  The state of the stat	SEADORY THE SECOND COMMENTS THE SECOND COMMENT	San and San an
combination up to x%  Combination not compatible	N Z T Z A	The second secon	The second second second	The second section is a part of the second	The second second second second		The second section is a second second second	The second come is confident and the second come in confident and		
Combination not studied	COMMON CONCENTRATION(S)									
API/DCI	88									
Adapalene	0.1% to 0.3%	0	0	0	0	0	0	0/0	0	0
Alpha arbutin Alfatradiol (17a-estradiol)	0.5% to 2% 0.025 to 0.05%	0	0	0	0	0	0	O*	0	0
Aloe vera extract	0.5 to 10%	0	0	0	0	8% 🔾	5% 🔾	0	0	0
Alpha bisabolol	0.5 to 2% 0.5 to 5%	0	0	0	0	0	0	O*	1% O	0
Ammonium lactate	1 to 12%	0	0	10% 🔾	10% 🔾	8% 🔾	×	0	0	0
Anthraline/dithranol Arginine HCl	0.05 to 3% 2.5%	0	0	0	0	0	×	0	O X	0
Ascorbic acid (vit. C)	5 to 15%	0	0	0	0	0	×	0	10% 🔾	0
	5 to 20% 10 to 20%	0	O X	0	0	0	0	0	O X	0
Azelaic acid	10 to 25%	0	0	0	0	0	0	0*	0	0
Benzoyl peroxide Benzyl benzoate	2.5 to 10% 25%	0	0	×	0	× 0	5% O	0	0	0
Betamethasone dipropionate	0.05%	0	0	0	0	0	0	0	0	0
Betamethasone valerate	0.025 to 0.1%	0	0	0	0	0	0	0	0	0
Brimonidine tartrate Caffeine	0.2 to 0.5% 1 to 2%	0	0	0	0	0	0	O*	0	0
Chamomile extract	0.5 to 5%	0	0	0	0	0	0	0	0	0
Ciclopirox olamine Clindamycin HCl	1% 1 to 3%	0	0	0	0	0	0	O O*	0	0
Clobetasol propionate	0.05%	0	0	0	0	0	0	0	0	0
Clotrimazole Coal tar crude (pix lithanthracis)	1 to 2%	0	0	0	0	0	0	0	0	0
Coal tar solution (LCD)	5 to 20%	10% 🔾	0	10% 🔾	10% 🔾	0	0	0	0	0
Cyanocobalamin (vit. B12) Cyproterone acetate	0.07% 0.5% to 2%	0	0	0	0	0	0	0	0	0
Dapsone	5 to 10%	0	0	0	0	0	0	<b>O</b> *	0	0
Desonide	0.05 to 0.1%	0	0	0	0	0	0	0	0	0
Desoximetasone Dexpanthenol	0.25% 0.5 to 5%	0	0	0	0	0	0	0	0	0
Diclofenac sodium	3%	0	0	0	0	0	×	0	0	0
Diflucortolone valerate  Ellagic acid	0.1 to 0.3% 0.25 to 1%	0	0	0	0	0	0	O*	0	0
Enoxolone	0.5 to 2.5%	0	0	0	0	0	0	<b>O</b> *	0	0
Erythromycin	0.5 to 4% 1 to 4%	0	0	0	0	0	0	O*	0	0
Estriol	0.1 to 1%	0	0	0	0	0	0	0	0	0
Fluocinolone acetonide	0.1% 0.01 to 0.1%	0	0	0	0	0	0	0	0	0
Glycerol	0.5 to 20%	0	0	0	0	8% 🔾	5% 🔾	0	0	0
Glycolic acid	2 to 10% 5 to 15%	0	0	0	0	0	0	O*	0	0
Hyaluronic acid	0.2 to 2.5%	0	×	×	×	0	×	0	×	0
Hydrocortisone Hydrocortisone acetate	0.25 to 2.5% 0.25 to 2.5%	0	0	0	0	0	0	0	0	0
Hydroquinone	2 to 10%	0	0	×	×	*	×	<b>O</b> *	×	0
Ivermectin Ketoconazole	1 to 5%	0	0	0	0	0	0	O*	0	0
Kojic acid	1 to 4%	0	0	0	0	0	0	<b>O</b> *	0	0
Lactic acid Latanoprost	1 to 20% 0.005%	0	10% 🔾	0	0	0	0	0	120 days	0
Lidocaine	0.5 to 10%	5% 🔾	0	0	0	0	0	0	O	0
Lidocaine HCI	0.5 to 5%		5% 🔾	0	0	0	×	O O*	0	0
Mandelic acid Melatonin	2 to 10% 0.0033 to 0.1%	0	0	0	0	0	0	0	0	0
Menthol	1 to 3%	0	0	0	0	0	0	0	0	0
Metronidazole	0.5 to 3% 0.75 to 5%	0	0	0	0	× 0	0	0	0	0
Minoxidil	2 to 5%	0	0	0	0	0	0	0	0	180 days
Mometasone furoate	0.1% 1 to 5%	0	0	0	0	0	0	0	0	0
Nicotinamide (vit. B3)	2 to 5%	0	0	0	0	0	0	0	0	0
Permethrin Progesterone	5 to 15% 0.5 to 2%	0	0	0	0	0	0	0	0	0
Prostaquinon™	3%	0	0	0	0	0	0	0	0	3% 🔾
Resorcinol Retinol (vit. A)	15% 0.4%	0	0	×	×	•	× •	0	0	0
Salicylic acid	0.4% 0.5 to 20%	0	0	10% 🔾	10% 🔾	0	5% 🔾	0	0	0
Shea butter	1 to 20%	0	0	×	0	8% 🔾	5% 🔾	0	×	0
Spironolactone	1% 0.5 to 2%	0	0	0	0	0	0	0	0	0
Sulfur	5 to 10%	0	0	0	0	8% 🔾	5% 🔾	0	0	0
Tacrolimus Tetracycline HCl	0.03 to 0.5% 2 to 3%	0	0	0	0	0	×	0	0	0
Tocopherol (vit. E)	0.5 to 20%	0	0	0	0	8% 🔾	5% 🔾	0	0	0
Tranexamic acid Tretinoin (vit. A acid)	1 to 5% 0.01 to 0.1%	0	0	0	0	0	0	0	0	0
Triamcinolone acetonide	0.01 to 0.1% 0.025 to 0.1%	0	0	0	0	0	0	0	0	0
Urea Zinc oxide	5 to 40% 1 to 40%	× •	10% 🔾	25% 🔾	10% 🔾	8% 🔾	5% 🔾	0	0	0
Zinc oxide Zinc pyrithione	1 to 40%	0	0	0	0	0	5% 0	0*	0	0
Zinc sulfate	1 to 10%	0	0	0	0	8% 🔾	5% 🔾	0	×	0

<sup>\*</sup> Estimated beyond-use date (compatibility study in progress). In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 30 days.



## Please refer to the Compounding Matters formulations database at fagron.gr for all compounding methods and storage conditions.

Fagron Advanced Derma vehicles allow for stable preparations with a broad range of APIs and DCIs. Combinations that have been scientifically studied for chemical, physical and microbiological stability are included in this Fagron Advanced Derma compatibility table.

The compatibility table and Fagron's free Compounding Matters formulations database support health professionals in exploring possible treatment options. APIs or DCIs that are not included in these resources can also form elegant, stable compounded preparations that help to improve patient comfort and compliance. When no study data is available for a specific API or DCI, it is recommended that the pharmacist assigns an appropriate expiry date based on internal protocols, risk analysis or guidelines from accredited pharmacopoeias.

Disclaimer: While a great deal of effort has been spent to ensure the accuracy of the formulations contained herein, no claims are made as to the uses, safety, efficacy or bioavailability of these recommendations. The content of this table cannot be construed as (medical) advice, recommendation or opinion

FADCT09



T +30 24310 83633-5 F +30 24310 83615 www.fagron.gr Fagron Hellas 12 km N.R. Trikala - Larisa P.C. 42100, P.O. Box 32 Trikala, Greece



